Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. The team provides drug discovery services to find novel ways to fight incredibly serious diseases. Private equity-backed since by Five Arrows Principal Investments, we operate fully-enabled research facilities in Nottingham and Alderley Park, UK, which house over 400 research scientists (over 80% of whom hold a PhD). Additional offices are located in Cambridge, MA, and South San Francisco, CA, in the US.
Sygnature’s experienced ‘drug-hunters’ are interested in drastically improving outcomes for patients with serious diseases, discovering the foundations for the next generation of medicine. They have the professional skills and expertise required to undertake the most demanding of research programs, and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate.
Since 2011, 36 compounds, discovered by Sygnature for partners, have entered pre-clinical development. Twenty-one of these have progressed to clinical trials (Phases I, II and III).
Sygnature Discovery is a leading independent CRO which provides truly integrated drug discovery solutions. The scientific team provides drug discovery services to identify and develop novel drug candidates in a broad range of therapeutic areas including oncology, neuroscience and inflammation. Private equity-backed since 2017 currently with 5 Arrows (Rothchild), we operate fully-enabled research laboratories in Nottingham and Alderley Park, UK, which house over 400 research scientists (over 80% of whom hold a PhD). Additional offices are located in Macclesfield UK, Cambridge, MA, and South San Francisco, CA, in the US.
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.